Grape Polyphenols Prevent Fructose-Induced Oxidative Stress and Insulin Resistance in First-Degree Relatives of Type 2 Diabetic Patients

To cite this version:
Marie Hokayem, Emilie Blond, Hubert Vidal, Karen Lambert, Emmanuelle Fouilloux-Meugnier, et al.. Grape Polyphenols Prevent Fructose-Induced Oxidative Stress and Insulin Resistance in First-Degree Relatives of Type 2 Diabetic Patients. Diabetes Care, American Diabetes Association, 2013, 36 (6), pp.1454 - 1461. 10.2337/dc12-1652. hal-01837559

HAL Id: hal-01837559
https://hal.archives-ouvertes.fr/hal-01837559
Submitted on 12 Mar 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Grape Polyphenols Prevent Fructose-Induced Oxidative Stress and Insulin Resistance in First-Degree Relatives of Type 2 Diabetic Patients

Marie Hokayem, MS1,2  Emile Blond, PharMD3,4  Hubert Vidal, PhD1,4  Karen Lambert, PhD1,2  Emmanuelle Meugnier, PhD3  Christine Feillet-Coudray, PhD5  Charles Coudray, PhD3  Sandra Pesenti, BS3  Cedric Luyton, MD, PhD4  Stephanie Lambert-Porchon, MD, PhD4  Valerie Sauvinet, MS1,4

Christine Fedou, MD, PhD1,2,6  Jean-Frederic Brun, MD, PhD1,2,6  Jennifer Riusset, PhD1,3,4  Catherine Bisbal, PhD1,2  Ariane Sultan, MD, PhD1,2,6  Jacques Mercier, MD, PhD1,2,6  Joelle Goudable, PhD1,2  Anne-Marie Dupuy, MD, PhD7  Jean-Paul Cristol, MD, PhD3,4  Martine Laville, MD, PhD3,4  Antoine Avignon, MD, PhD1,2,6

OBJECTIVE—To assess the clinical efficacy of nutritional amounts of grape polyphenols (PPs) in counteracting the metabolic alterations of high-fructose diet, including oxidative stress and insulin resistance (IR), in healthy volunteers with high metabolic risk.

RESEARCH DESIGN AND METHODS—Thirty-eight healthy overweight/obese first-degree relatives of type 2 diabetic patients (18 men and 20 women) were randomized in a double-blind controlled trial between a grape PP (2 g/day) and a placebo (PCB) group. Subjects were investigated at baseline and after 8 and 9 weeks of supplementation, the last 6 days of which they all received 3 g/kg fat-free mass/day of fructose. The primary end point was the protective effect of grape PPs on fructose-induced IR.

RESULTS—In the PCB group, fructose induced 1) a 20% decrease in hepatic insulin sensitivity index (P < 0.05) and an 11% decrease in glucose infusion rate (P < 0.05) as evaluated during a two-step hyperinsulinemic-euglycemic clamp, 2) an increase in systemic (urinary F2-isoprostanes) and muscle (thiobarbituric acid–reactive substances and protein carbonylation) oxidative stress (P < 0.05), and 3) a downregulation of mitochondrial genes and decreased mitochondrial respiration (P < 0.05). All the deleterious effects of fructose were fully blunted by grape PP supplementation. Antioxidative defenses, inflammatory markers, and main adipokines were affected neither by fructose nor by grape PPs.

CONCLUSIONS—A natural mixture of grape PPs at nutritional doses efficiently prevents fructose-induced oxidative stress and IR. The current interest in grape PP ingredients and products by the global food and nutrition industries could well make them a stepping-stone of preventive nutrition.
circumference > 80 cm for women and > 94 cm for men; consumed < 30 g/day alcohol; and had a sedentary lifestyle (12). All subjects had blood pressure < 140/90 mmHg and normal ferritinemia (75–300 ng/mL) and thyroid function; hepatic enzymes (γ-glutamyl transpeptidase, alanine aminotransferase [ALT], and aspartate aminotransferase [AST]) were three or less times the normal values, serum creatinine was ≤ 1.50 μmol/L, high-sensitivity C-reactive protein (hs-CRP) < 8 mg/L, and fasting plasma glucose < 110 mg/dL.

Five subjects were enrolled but dropped out for difficulties during blood withdrawal (one PCB) or for personal reasons (two PCB and two PP) not linked to secondary effects regarding study protocol. The study was approved by the ethics committee of Montpellier. All participants gave written informed consent.

**Anthropometry and body composition measurements**
Standing height was measured using a stadiometer. Body weight and hip and waist circumferences were measured in the fasting state before metabolic analysis. Body composition was evaluated by bioelectrical impedance (BodyStat). Blood pressure was measured after a 15-min rest period using an automated blood pressure device with participants in the recumbent position. A minimum of four blood pressure measurements was taken 2 min apart.

**Study design**
Each subject was studied on three occasions: 1) at the beginning of the study, 2) after 8 weeks of supplementation with 2 g/day grape PPs or PCB, and 3) after 9 weeks of supplementation with grape PPs or PCB while subjects also had ingested 3 g fructose/kg fat-free mass/day as a 20% fructose solution with the three main meals during the 6 days preceding the final test date (Supplementary Fig. 2). Subjects were assigned to the grape PP or PCB supplementation groups by randomization in blocks of four individuals each, sequentially allocated to grape PPs and PCB using a randomization list that was drawn up for each of the two recruiting centers. Grape PPs (Supplementary Table 1) or identical-looking PCB (microcrystalline cellulose, Avicel; UNITHER pharmaceuticals, Bordeaux, France) capsules (333.33 mg grape extract/PCB per capsule) were to be taken daily: three during breakfast and three at dinner. Evaluation of compliance (≥ 80% of the capsules taken) was done before starting the tests by counting the number of returned capsules after 4, 8, and 9 weeks from baseline. Volunteers were instructed to avoid polyphenol-rich foods and to follow a balanced, isoenetic diet, which was controlled by a food diary during the 3-day period preceding each test and assessed with GENI software (Micro 6, Villers-les-Nancy, France). Intake of dietary polyphenols was further evaluated using phenol explorer (version 1.5.7, INRA, Clermont-Ferrand). Subjects were advised to avoid vigorous physical activity during the 6 days preceding each test.

**Hyperinsulinemic-euglycemic clamp**
Investigations were performed after an overnight fast. Insulin sensitivity was assessed using the hyperinsulinemic-euglycemic clamp as previously described (13), with a 1 mU·kg⁻¹·min⁻¹ insulin infusion for 120 min. Glucose infusion rate (GIR) was calculated during the final 30 min of the clamp. All subjects underwent a two-step insulin clamp (0.2 and 1 mU·kg⁻¹·min⁻¹). However, owing to regulatory issues, only the 19 subjects in Lyon (10 PP and 9 PCB) received an initial 4-h [6,6-²H₁]-glucose (Eurisotop, St. Aubain, France) infusion to determine basal endogenous glucose production and its inhibition during the 0.2 mU·kg⁻¹·min⁻¹ insulin infusion (14). During the clamp, blood samples were drawn every 10 min to monitor blood glucose concentration using a glucose meter (ACCU-CHEK Performa). Fasting hepatic insulin sensitivity index was calculated according to the methodology of Matsuda et al. (15).

**Muscle biopsies**
Before the clamp, a percutaneous biopsy of the vastus lateralis was obtained under local anesthesia (lidocaine 2%) either with Weil Blakesley pliers in Lyon (14) or using a 5-mm Bergstrom needle in Montpellier (16). A muscle sample was immediately frozen in liquid nitrogen and stored at −80°C for further analysis. For the 19 subjects in Montpellier (10 PP and 9 PCB), 80 mg muscle was permeabilized to study mitochondrial respiration and 50 mg were incubated for 15 min in PBS at 30°C in the presence or absence of human insulin (1 μmol/L) (Umuline RAPIDE; Lilly France) to study molecular mechanisms of insulin signaling.

**Analytical procedures**
Plasma glucose was measured by the glucose oxidase method (AU2700 Olympus; Beckman Coulter, O’Callaghan’s Mills, Co. Clare, Ireland) and nonesterified fatty acids via an enzymatic method (Wako, Neuss, Germany). Hepatic enzymes (AST, ALT, and γ-glutamyl transpeptidase), total cholesterol, HDL cholesterol, and triglycerides were determined using spectrophotometric methods (AU2700 Olympus; Beckman Coulter), and LDL cholesterol was calculated using the Friedewald formula; LDL size was determined by electrophoretic migration on polyacrylamide gel (Spirale, Dijon, France).

Plasma insulin was measured by radioimmunoassay (BI-Insulin IRMA kit; CIS Bio, Gif sur Yvette, France). Plasma concentrations of leptin, ghrelin, adiponectin, and resistin were evaluated by ELISA (R&SD System), and cytokines, including interleukin (IL)-1α, IL-1β, IL-6, IL-4, tumor necrosis factor-α, and interferon-γ, were determined using multiplex Biochip Technology from Randox Laboratories (Crumlin, U.K.). The concentration of hs-CRP was determined by immuno-turbidimetry (Randox).

**Western blots**
Muscle samples were homogenized in a lysis buffer containing 30 mmol/L HEPES, 40 mmol/L NaCl, 5 mmol/L EDTA, 2 mmol/L EGTA, and 210 mmol/L sucrose with phosphatase and protease inhibitors and centrifuged for 10 min at 10,000g. Primary antibodies used included phospho-Akt (Ser473) (cat. no. 4060; Cell Signaling), total Akt (cat. no. 9171; Cell Signaling), and UCP3 (AB3044; Millipore). α-Tubulin (16074; Sigma-Aldrich) was used as a loading control.

**Protein carbonylation and determination of lipid oxidation in plasma, tissue, and urine**
The Oxyblot Oxidized Protein Detection kit, purchased from Chemicon (Hampshire, U.K.), was used to define muscle protein carbonylation levels as previously described (17). Lipid peroxidation levels were measured as thiobarbituric acid–reactive substances (TBARS) in plasma and in tissue homogenates as previously described (18) and as urinary F2-isoprostanes determined by gas chromatography–mass spectrometry (Therofinnigan, Courtaboef, France) (19). F2-isoprostanes concentrations are reported in relation to urinary creatinine (Beckman Coulter).

**Determination of antioxidant activities in plasma and tissues**
Blood and tissue total glutathione, tissue catalase/glutathione peroxidase, and...
Polyphenols stop fructose metabolic alterations

plasma and/or tissue total and manganese superoxide dismutases (SOD and MnSOD, respectively) were measured as previously described (18).

Mitochondrial function and respiration

Mitochondrial respiratory variables were analyzed in situ on fresh permeabilized skeletal muscle fibers of subjects recruited in Montpellier as previously described (16). Basal (V0) and maximal (Vmax) respiration rates were recorded in the presence of pyruvate/malate (10 mmol/L) or palmitoyl-l-carnitine (40 μmol/L). Respiration rates were expressed in micromoles of O2 per minute per gram of muscle fibers.

Citrate synthase activity

Muscle extracts were homogenized in 10 mmol/L Tris HCl (pH 7.4). Citrate synthase activity was measured with 0.5 mmol/L oxaloacetate, 0.3 mmol/L acetyl-CoA, 0.1 mmol/L 5,5′-dithiobis-2-nitro-benzoic acid, and 100 mmol/L Tris HCl (pH = 8.0). Enzyme activity was monitored by recording the changes in absorbance at 412 nm over 2.5 min at 37°C as suggested by Srere (20), normalized to tissue weight, and expressed as micromoles per minute per gram of tissue.

Gene expression analyses

Microarray analysis. RNA profiling in muscle biopsies was performed using a Human GE 4×44K v2 Microarray kit (Agilent Technologies, Massy, France). Briefly, 200 ng total RNA isolated from frozen muscle samples was labeled using the Low Input Quick Amp Labeling kit.

Table 1—Subjects’ characteristics at baseline and throughout study exploration visits

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Post–8 weeks of supplementation</th>
<th>Post–6 days of fructose after 8 weeks of supplementation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PCB</td>
<td>Grape PP</td>
<td>PCB</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>18</td>
<td>20</td>
</tr>
<tr>
<td>Men/women (N/N)</td>
<td>7/11</td>
<td>11/9</td>
<td>7/11</td>
</tr>
<tr>
<td>Age (years)</td>
<td>48.4 ± 2.0</td>
<td>49.7 ± 1.9</td>
<td>48.4 ± 2.0</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>81.1 ± 2.4</td>
<td>82.6 ± 2.8</td>
<td>81.0 ± 2.4</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>29.1 ± 0.7</td>
<td>29.3 ± 0.6</td>
<td>29.0 ± 0.6</td>
</tr>
<tr>
<td>Fat mass (%)</td>
<td>35.2 ± 1.8</td>
<td>31.2 ± 2.1</td>
<td>35.3 ± 1.8</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>98.2 ± 2.1</td>
<td>100.1 ± 1.8</td>
<td>98.1 ± 2.3</td>
</tr>
<tr>
<td>hs-CRP (mg/L)</td>
<td>2.4 ± 0.6</td>
<td>2.5 ± 0.4</td>
<td>2.3 ± 0.6</td>
</tr>
<tr>
<td>AST (units/L)</td>
<td>23.1 ± 1.8</td>
<td>26.0 ± 1.9</td>
<td>22.8 ± 1.8</td>
</tr>
<tr>
<td>ALT (units/L)</td>
<td>28.4 ± 4.6</td>
<td>34.0 ± 4.9</td>
<td>26.8 ± 4.9</td>
</tr>
<tr>
<td>γ-glutamyl transpeptidase (units/L)</td>
<td>27.8 ± 2.9</td>
<td>30.2 ± 4.4</td>
<td>26.7 ± 2.8</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>121.6 ± 3.3</td>
<td>115.4 ± 2.5</td>
<td>117.9 ± 3.4</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>72.2 ± 2.3</td>
<td>70.4 ± 1.4</td>
<td>70.1 ± 2.0</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>1.07 ± 0.07</td>
<td>1.19 ± 0.13</td>
<td>1.07 ± 0.10</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>5.49 ± 0.20</td>
<td>5.28 ± 0.16</td>
<td>5.41 ± 0.23</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/L)</td>
<td>1.52 ± 0.11</td>
<td>1.36 ± 0.05</td>
<td>1.52 ± 0.10</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/L)</td>
<td>3.49 ± 0.17</td>
<td>3.38 ± 0.14</td>
<td>3.40 ± 0.20</td>
</tr>
<tr>
<td>LDL size (nm)</td>
<td>25.8 ± 0.1</td>
<td>25.5 ± 0.1</td>
<td>25.8 ± 0.1</td>
</tr>
<tr>
<td>Fasting glucose (mmol/L)</td>
<td>5.3 ± 0.2</td>
<td>5.4 ± 0.1</td>
<td>5.3 ± 0.2</td>
</tr>
<tr>
<td>Fasting insulin (μU/L)</td>
<td>4.7 ± 0.5</td>
<td>4.4 ± 0.4</td>
<td>4.3 ± 0.4</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>5.4 ± 0.1</td>
<td>5.4 ± 0.1</td>
<td>5.4 ± 0.1</td>
</tr>
<tr>
<td>GFR (mg/kg/min)</td>
<td>6.85 ± 0.55</td>
<td>6.03 ± 0.43</td>
<td>7.38 ± 0.57</td>
</tr>
<tr>
<td>Basal endogenous glucose production (mg/kg/min)</td>
<td>2.08 ± 0.07</td>
<td>2.10 ± 0.05</td>
<td>2.14 ± 0.06</td>
</tr>
<tr>
<td>Endogenous glucose production at low insulin: mean f00–120 min (mg/kg/min)</td>
<td>0.44 ± 0.11</td>
<td>0.38 ± 0.13</td>
<td>0.75 ± 0.24</td>
</tr>
<tr>
<td>Fasting hepatic insulin sensitivity index ix</td>
<td>13.6 ± 2.6</td>
<td>10.9 ± 1.0</td>
<td>11.9 ± 1.5</td>
</tr>
<tr>
<td>Urinary F2-isoprostanes (pmol/mmol creatinine)</td>
<td>520 ± 43</td>
<td>494 ± 37</td>
<td>463 ± 39*</td>
</tr>
<tr>
<td>TBARS (mmol/g tissue)</td>
<td>35.8 ± 4.8</td>
<td>27.2 ± 3.5</td>
<td>26.3 ± 2.1*</td>
</tr>
<tr>
<td>Caloric intake (kcal)</td>
<td>1,858 ± 64</td>
<td>1,978 ± 133</td>
<td>1,780 ± 126</td>
</tr>
<tr>
<td>Protein intake (g)</td>
<td>89.7 ± 5.6</td>
<td>86.5 ± 5.9</td>
<td>87.1 ± 6.2</td>
</tr>
<tr>
<td>Carbohydrate intake (g)</td>
<td>195.1 ± 18.9</td>
<td>207.6 ± 16.3</td>
<td>190.8 ± 17.8</td>
</tr>
<tr>
<td>Fat intake (g)</td>
<td>80.9 ± 6.0</td>
<td>83.9 ± 6.8</td>
<td>72.8 ± 5.2</td>
</tr>
</tbody>
</table>

Data are means ± SEM unless otherwise indicated. At baseline, there were no significant differences between groups (18 PCB and 20 PP). *Significant difference before (8 week post-PPs/PCB) and after (8–9 weeks) fructose load (P < 0.05) within each group via the Wilcoxon signed rank sum test. †Fasting hepatic insulin sensitivity index was calculated as follows: 100/hepatic glucose output (mg·kg⁻¹·min⁻¹). Values do not take fructose overload into consideration. ‡Muscle TBARS were available for only eight PCB and eight PP volunteers.
(CY3) from Applied Biosystems, and microarrays were hybridized and scanned following the manufacturer’s instructions. The data were normalized using the Agilent FE one-color scenario (GeneSpring GX software). After filtration, statistical analysis was performed on 26,220 probes with the Limma package (21). The dataset is available from the GEO database (GSE35764).

**RT real-time PCR.** First-strand cDNAs were synthesized from 500 ng skeletal muscle. Total RNA and real-time PCR assays were performed as previously described (22). Values were normalized using hypoxanthine guanine phosphoribosyltransferase. RT-PCR primer sequences are listed in Supplementary Table 2.

**Statistical analysis**

Statistical analysis was performed with JMP 9.0.0 software, with data expressed as means ± SEM. To overcome the non-normal distribution of most parameters, we analyzed data using a repeated-measures general linear model; when significance was reached (P < 0.05), we confirmed results with Mann-Whitney U test for comparisons between the PCB and grape PP groups at each time point (baseline, post–8 weeks of PCB/grape PP supplementation, and post–6 days of fructose combined with PCB/grape PP supplementation) and with Wilcoxon signed rank sum for within-group (pre- and postinterventions) comparisons. Correlations were evaluated using Spearman rank correlation tests. Statistical significance was considered for P values <0.05 with no adjustment for multiple comparisons.

**RESULTS**

**Subjects’ characteristics, adherence to the study protocol, and adverse events**

Thirty-eight subjects completed the study and were included in the per-protocol analysis. They were aged 31–65 years, with BMIs between 25.1 and 36.5 kg/m² and waist circumference 80–118 cm for women and 94–113 cm for men. At baseline, the groups did not differ in terms of anthropometric measures; food, energy, nutrient and PP intake; or levels of plasma lipids and glucose or urinary F2-isoprostanes (Table 1). According to participants’ own reports and results of physical examination and laboratory parameters, no adverse events occurred in either supplementation group. Since decreased intestinal absorption of iron has been reported with high intakes of PPs, plasma ferritin was measured both at inclusion and at the end of the study. No significant decrease in this parameter was noted, and no subject was below the normal threshold values at the beginning or end of the study.

**Effects of 8-week grape PP supplementation**

Surprisingly, after 8 weeks of supplementation we noted a decrease in urinary F2-isoprostanes and in muscle TBARS in the PCB group that was not found in the grape PP group, with no effects on the other parameters measured (Table1). Muscle protein carbonylation as well as antioxidative capacities, i.e., plasmatic vitamin E, blood glutathione-to-GSSG ratio, erythrocyte SOD, and the muscle enzymatic activities of catalase, glutathion peroxidase (GPx), SOD, and MnSOD, remained unaffected (Supplementary Table 3). No significant effects of grape PP supplementation were found on plasma cytokines (IL-1α, IL-1β, IL-6, IL-4, tumor necrosis factor-α, and interferon-γ), on the main adipokines (adiponectin, leptin, and resistin), or on ghrelin (Supplementary Table 4). Importantly, insulin action, as measured by hyperinsulinemic clamps, was unaffected (Table 1).

**Metabolic consequences of HFrD**

Fructose load’s main effects are described in Table 1. After 6 days of HFrD, a significant increase of 300 g body wt was found in the PCB group with no alteration in body composition. HFrD increased fasting triglycerides ~30% in both groups, with a parallel decrease in fasting HDL cholesterol. A decrease in plasma LDL cholesterol associated with a decrease in LDL particle size (P < 0.01, Table 1) was noted only in the PCB group and not in the PP group. Neither in the PCB nor in the grape PP group did HFrD change plasma cytokine, plasma adipokines, or plasma ghrelin levels (Supplementary Table 4).

**Effects of HFrD on oxidative stress and protective effect of grape PP supplementation**

HFrD significantly increased urinary F2-isoprostanes (Fig. 1A) and muscle TBARS (Fig. 1B) in the PCB group, whereas grape PP supplementation protected against this induction of oxidative stress markers. At the end of the fructose load, the level of muscle protein carbonylation was significantly higher in the PCB group compared with the grape PP group (Fig. 1C). Antioxidative capacities, i.e., plasmatic vitamin E, blood glutathione-to-GSSG ratio, erythrocyte SOD, and the muscle enzymatic activities of catalase, GPx, SOD, and MnSOD, remained unaffected during the fructose load in both groups (Supplementary Table 3).

**Effects of HFrD on IR and protective effect of grape PP supplementation**

A 20% reduction of the fasting hepatic insulin sensitivity index was noted after HFrD (Table 1), associated with an 11%
Polyphenols stop fructose metabolic alterations

Effects of grape PP supplementation and of HFrD on transcriptomic profile and gene expression

Skeletal muscle transcriptomic profile was not significantly modified by the 8-week grape PP supplementation, with only 66 probes differentially regulated between both groups (P < 0.01 with moderated t test) (Supplementary Table 5). We did not reveal function or pathway enrichment in this small set of genes using functional profiling tools such as Babelomics or DAVID. In contrast, HFrD was accompanied by a differential regulation of 277 genes in skeletal muscle between the two groups (Supplementary Table 6). Functional profiling analysis enlightened a specific enrichment in mitochondrial genes including respiratory chain electron transport and oxidative phosphorylation (OXPHOS) (Fig. 2A). Importantly, most of these differentially regulated genes were downregulated in response to HFrD in the PCB group, while grape PP supplementation counteracted this effect (Supplementary Table 6).

Reverse transcriptase–quantitative PCR and Western blots further confirmed grape PPs’ protective effect against the aftermath of HFrD on key skeletal muscle mitochondrial genes and proteins, as shown in Fig. 2 for CKMT2 (Fig. 2B), CPT1B (Fig. 2C), and UCP3 mRNA expression (Fig. 2D). A significant decrease was also noted for the mRNA of peroxisome proliferator–activated receptor γ coactivator (PGC)-1α, a central regulator of mitochondrial biogenesis and function (−23% [Fig. 2E]). Regarding UCP3, the fructose-induced reduction in mRNA levels in the PCB group was associated with a trend for a decrease in UCP3 (59% reduction, P = 0.08) (Supplementary Fig. 5). All of these effects were prevented by grape PP supplementation.

Effects of HFrD on skeletal muscle mitochondrial function and protective effect of grape PP supplementation

Mitochondrial function was evaluated by oximetry on permeabilized muscle fibers. Both Vmax and Vrmax rates for pyruvate (Fig. 3A and B) and palmitoyl-l-carnitine (Fig. 3C and D) were decreased in the PCB group by HFrD, while they were significantly increased in the grape PP group. Furthermore, in the PCB group mitochondrial function variation was associated with insulin response, as evidenced by a strong negative correlation between Vmax palmitoyl-l-carnitine change during fructose load and GIR fluctuation (r = −0.97, P < 0.001); this relationship was not found in the grape PP group (Supplementary Fig. 6A and B). When results were corrected for mitochondrial content (citrate synthase activity), fructose had no effect on basal respiration rate (Fig. 3A and C), whereas Vmax remained decreased (Fig. 3B and D), indicating a joint effect on mitochondrial density and function.
PPs) on the correlations tests; data are means ± SEM. *P < 0.05 for statistical pre- and postintervention comparisons within each group via the Wilcoxon signed rank sum test. #P < 0.05 for intergroup comparisons by Mann-Whitney U tests. Correlations were established with Spearman rank correlations tests; data are means ± SEM.

CONCLUSIONS—The main finding of the current study is the demonstration that 9 weeks of supplementation with nutritional doses of grape PPs protects against fructose-induced oxidative stress and IR. Microarray analysis demonstrated that expression of many oxidative and mitochondrial genes, including OXPHOS genes and CPT1, was reduced in response to HFrD in skeletal muscle. A potential contribution to this observation in IR may be inferred from other studies reporting that expression of OXPHOS genes is decreased and multiple energy metabolism genes’ expression is altered in the context of type 2 diabetes in humans (23–25) and that a decrease in CPT activity, which transports long-chain acyl-CoA into the mitochondria, may lead to intracellular lipid accumulation triggering IR (26).

We further demonstrated that fructose has detrimental effects on mitochondrial respiration when either pyruvate or palmitoyl-carnitine was used as a substrate. This effect appears to be related both to variations in mitochondrial density as reflected by the lack of reduction in mitochondrial basal respiration by fructose when data were corrected for mitochondrial content (citrate synthase activity) and to altered function as exemplified by the decreased Vmax rate corrected for mitochondrial content in response to fructose. Fructose impairment of mitochondrial gene expression and mitochondrial function could result from altered expression of PGC-1α, a critical transcriptional regulator of nuclear-encoded mitochondrial genes whose reduced expression and activity has been related to IR and was suggested to be a primary feature of prediabetes pathophysiology (24).

As oxidative stress participates in skeletal muscle mitochondrial dysfunction, including altered biogenesis (27), it is tempting to speculate that fructose-induced mitochondrial alterations were related to oxidative stress. Our data demonstrating that grape PP supplementation prevents both oxidative stress in the presence of fructose and the downfall of mitochondrial function with maintenance of mitochondrial gene expression at normal levels in skeletal muscle support this hypothesis.

The protective effect of grape PPs on muscle oxidative stress and mitochondria was associated with maintenance of insulin sensitivity in the face of fructose overload. We found a negative correlation between fructose-induced changes of urinary F2-isoprostanes and GIR during the clamp, suggesting a link between oxidative stress and fructose-induced IR. Similarly, there was a strong negative correlation between the decrease in GIR and Vmax palmitoyl-carnitine variations during fructose overload (r = –0.97), powerfully supporting a direct association between fructose-induced decreased skeletal muscle mitochondrial function and IR. Therefore, by promoting mitochondrial biogenesis, reducing oxidative stress, and facilitating the uncoupling of oxidative metabolism, grape PPs may help maintain high levels of substrate oxidation while limiting free radical production, explaining their protective effect with respect to fructose-induced IR.

Major adipokines and hormones were not affected by grape PP supplementation, which is somewhat different from what is seen in animal models with grape seed procyanidin modulating CRP and adiponectin plasma levels in rats fed a hyperlipidic diet (28). This may suggest that, in the current study, grape PPs acted directly on metabolic tissues (skeletal muscle and liver) without systemic changes in regulating factors.

Whatever the mechanism, the protective effect of grape PPs on IR and oxidative stress was not associated with a reduction of fasting plasma triglycerides, indicating that it failed to impact the metabolic steps involved in hepatic de novo lipogenesis. Surprisingly, HFrD was associated with a decrease in LDL cholesterol in the PCB group only. Nevertheless, LDL particles in this group were more atherogenic as testified by a decrease in small-dense LDL size that was counteracted by grape PPs (29).

Even though resveratrol accounts for a very small portion of the grape PPs used in the present work, our results present similarities with the metabolic
effects of fructose metabolic alterations. Indeed, as for the latter, grape PPs were able to prevent diet-induced IR and potentially weight gain—effects that could be mediated by a control of mitochondrial biogenesis and respiration secondary to PGC-1α activation (30,31). We also obtained results similar to those of the clinical study of Timmers et al. (32) using resveratrol, including the upregulation of mitochondrial genes with an improved function and increased PGC-1α level favoring mitochondrial biogenesis; using the hyperinsulinemic-euglycemic clamp, we further complement the results of these authors showing an 11% improvement in homeostasis model assessment index after resveratrol (32).

Grape in itself is a panoply of polyphenols consisting mostly of anthocyanins and flavonols, including quercetin (33), much of which has also demonstrated multiple metabolic health benefits (6–8). Even though the dose of 2 g/day polyphenols used in the current study can be regarded as a high dose, it remains nevertheless compatible with the supply of a diet rich in red grapes, other fruits and vegetables, and eventually red wine.

By nature, the use of a polyphenol mixture does not enable us to identify clearly what components of the grape extract are causing any of the observed effects.

We would further like to recall that grape PPs are already used by the food industry in the form of dyes and tannins, notably in sugary foods (11). Our results constitute a basis for considering further work studying the effects of direct addition of PPs to foods containing fructose.

In conclusion, 9 weeks of grape PP supplementation secures an unwavering metabolic state in healthy overweight/obese first-degree relatives of type 2 diabetic subjects faced with a 6-day fructose overload, preventing liver and muscle IR while bearing no adverse effects. Future studies should investigate the effects of grape PP coadministration with processed food rich in fructose and their potential role in countering the metabolic syndrome.

Acknowledgments—This study was funded by the French National Research Agency Agence Nationale de la Recherche (Poly-OxResist-2007-A01375-48).

No potential conflicts of interest relevant to this article were reported. The authors thank the two major distilleries of the Languedoc-Roussillon area, Société Française de Distilleries and GRAP’SUD, for provision of the grape extracts.

M.H., E.B., H.V., K.L., M.L., and A.A. researched data, contributed to discussion, and reviewed, edited, and wrote the manuscript. E.M. researched data. C.F.-C. and C.C. contributed to discussion and reviewed and edited the manuscript. S.P., C.L., S.-L.P., V.S., C.F., J.-F.B., and J.R. researched data. C.B., A.S., J.M., J.G., A.-M.D., and J.-P.C. contributed to discussion and reviewed and edited the manuscript. A.A is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Parts of this study were presented in abstract form at the 72nd Scientific Sessions of the American Diabetes Association, Philadelphia, Pennsylvania, 8–12 June 2012.

The authors thank G. Fourrier (INRA UMR 866, Unité Dynamique Musculaire et Métabolisme), M.-C. Granat (University Hospital of Montpellier), and C. Bezes (University Hospital of Montpellier) for technical support as well as A. Coma (University Hospital of Montpellier) and A. Cadene (University Hospital of Montpellier) for administrative work relating to the implementation of good clinical practice throughout the study. The authors also express deep gratitude to all of the recruited subjects and the members of the clinical and research teams of both investigation centers (Department of Nutrition-Diabetes, University Hospital of Montpellier, and the Rhône-Alpes Research Center for Human Nutrition, University Hospital of Lyon).

References


22. Bravard A, Lefai E, Meugnier E, et al. FTO is increased in muscle during type 2 diabetes, and its overexpression in myotubes alters insulin signaling, enhances lipogenesis and ROS production, and induces mitochondrial dysfunction. Diabetes 2011;60:258–268


